

On page 2 of the specification, above the first full paragraph, insert

Summary of the Invention

A2 On page 2 of the specification, between the first and second paragraphs, insert:

Brief Description of the Drawings

Figure 1 is a depiction of a tablet according to the present invention.

Detailed Description of the Invention

IN THE CLAIMS:

Please amend claim 6 as follows:

A3 6. The system of claim 1 wherein said pharmaceutically active agent is pseudoephedrine or its salts.

Please add claims 12-20 as follows:

A4 12. The osmotic system of claim 1, wherein said pharmaceutically active agent is an antitussive, antihistamine, expectorant or decongestant.

13. The osmotic system of claim 12, wherein said pharmaceutically active agent is chlorpheniramine or its salts, diphenhydramine, or dimenhydramine.

14. The osmotic system of claim 1, wherein said pharmaceutically active agent is cyclosporin, carmustine, carbamazepine, desmopreson, dihydroergotamine, fluorouracil, heparin sodium, ribavirin, sumatriptan succinate, flutamide, naltrexone HCl, terbutaline sulfate, triamterene, terazosin, parazosin, nifedipine, calcitonin, insulin, parathyroid hormone, or GLP-1.

15. The osmotic system of claim 7, wherein said first pharmaceutically active agent is an antitussive, antihistamine, expectorant or decongestant.

16. The osmotic system of claim 15, wherein said first pharmaceutically active agent is chlorpheniramine or its salts, diphenhydramine, or dimenhydramine.

17. The osmotic system of claim 15, wherein said first pharmaceutically active agent is pseudoephedrine or its salts.

18. The osmotic system of claim 7, wherein said first pharmaceutically active agent is cyclosporin, carmustine, carbamazepine, desmopreson, dihydroergotamine, fluorouracil, heparin sodium, ribavirin, sumatriptan succinate, flutamide, naltrexone HCl, terbutaline sulfate, triamterene, calcitonin, insulin, parathyroid hormone, or GLP-1.

19. The osmotic system of claim 15, wherein said second pharmaceutically active agent is loratidine, desloratidine, astemizole, norastemizole or ebastine.

20. The osmotic system of claim 7, wherein said first pharmaceutically active agent is pseudoephedrine or its salts, and said second pharmaceutically active agent is loratidine.

REMARKS

It is respectfully requested that the rejections of record be reconsidered and withdrawn in view of the following remarks.